These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 9603698)

  • 21. The current role of ACE-inhibitors for secondary prevention in cardiovascular disease; from pathogenesis to clinical practice.
    Voors AA; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2006 Feb; 20(1):69-73. PubMed ID: 16619108
    [No Abstract]   [Full Text] [Related]  

  • 22. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular therapies and risk for development of diabetes.
    Pepine CJ; Cooper-Dehoff RM
    J Am Coll Cardiol; 2004 Aug; 44(3):509-12. PubMed ID: 15358012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heart failure: clinical problem and management issues.
    Nicklas JM; Bleske BE; Van Harrison R; Hogikyan RV; Kwok Y; Chavey WE
    Prim Care; 2013 Mar; 40(1):17-42. PubMed ID: 23402460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardioprotective Exercise and Pharmacologic Interventions as Complementary Antidotes to Cardiovascular Disease.
    Quindry JC; Franklin BA
    Exerc Sport Sci Rev; 2018 Jan; 46(1):5-17. PubMed ID: 28885265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Special considerations for antihypertensive agents in dialysis patients.
    Redon J; Martinez F; Cheung AK
    Blood Purif; 2010; 29(2):93-8. PubMed ID: 20093810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Efficacy of angiotensin-converting enzyme inhibitors in secondary prevention].
    Ceconi C; Mastrorilli F; Squasi PA; Gaitani S; Guardigli G; Ferrari R
    Ital Heart J; 2005 Nov; 6 Suppl 7():5S-13S. PubMed ID: 16485512
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SaM (Screening and Monitoring) approach to cardiovascular risk-reduction in primary care--cyclic monitoring and individual treatment of patients at cardiovascular risk using the electronic medical record.
    Rabinowitz I; Tamir A
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):56-62. PubMed ID: 15703507
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: part 2.
    Bommer WJ
    Prev Cardiol; 2008; 11(4):215-22. PubMed ID: 19476574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Telmisartan prevents cardiovascular events in a broad group of at-risk patients.
    Baumhäkel M; Böhm M
    Expert Opin Pharmacother; 2009 Dec; 10(18):3113-7. PubMed ID: 19925045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impaired glucose tolerance and impaired fasting glucose--a review of diagnosis, clinical implications and management.
    Petersen JL; McGuire DK
    Diab Vasc Dis Res; 2005 Feb; 2(1):9-15. PubMed ID: 16305067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge.
    Lee HY; Cooke CE; Robertson TA
    J Manag Care Pharm; 2008 Apr; 14(3):271-80. PubMed ID: 18439049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal.
    Zanchetti A; Thomopoulos C; Parati G
    Circ Res; 2015 Mar; 116(6):1058-73. PubMed ID: 25767290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns.
    Haffner SM
    Am J Med; 2006 May; 119(5 Suppl 1):S3-9. PubMed ID: 16563945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Civilization stress, cardiovascular risk, evidence-based medicine, guidelines].
    Simon K
    Orv Hetil; 2009 May; 150(19):895-902. PubMed ID: 19403433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
    Borghi C; ; Rossi F;
    High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.